Stock Scorecard

Stock Summary for Lyell Immunopharma Inc (LYEL) - $0.43 as of 5/5/2025 8:35:49 PM EST

Total Score

9 out of 30

Safety Score

23 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LYEL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LYEL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LYEL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LYEL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LYEL (23 out of 100)

Stock Price Rating (Max of 10) 1
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for LYEL

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma ( ICML ) 2025 - Lyell Immunopharma ( NASDAQ:LYEL ) 5/1/2025 1:00:00 PM
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant... 5/1/2025 1:00:00 PM
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy ( RMAT ) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma 4/15/2025 1:00:00 PM
Lyell Immunopharma ( LYEL ) Upgraded to Strong Buy: Here's Why 1/22/2025 5:00:00 PM
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference 1/9/2025 2:00:00 PM
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma ( LYEL ) 12/31/2024 2:35:00 PM
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma ( LYEL ) 12/30/2024 2:35:00 PM
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma ( LYEL ) Looks Ripe for a Turnaround 12/13/2024 2:35:00 PM
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting 12/10/2024 2:00:00 AM
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors 11/18/2024 9:05:00 PM

Financial Details for LYEL

Company Overview
Ticker LYEL
Company Name Lyell Immunopharma Inc
Country USA
Description Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History
Last Day Price 0.43
Price 4 Years Ago 7.74
Last Day Price Updated 5/5/2025 8:35:49 PM EST
Last Day Volume 267,681
Average Daily Volume 672,689
52-Week High 2.88
52-Week Low 0.39
Last Price to 52 Week Low 10.26%

Valuation Measures
Trailing PE N/A
Industry PE 32.04
Sector PE 37.03
5-Year Average PE -2.87
Free Cash Flow Ratio 1.19
Industry Free Cash Flow Ratio 19.19
Sector Free Cash Flow Ratio 29.42
Current Ratio Most Recent Quarter 7.06
Total Cash Per Share 0.36
Book Value Per Share Most Recent Quarter 1.30
Price to Book Ratio 0.34
Industry Price to Book Ratio 7.60
Sector Price to Book Ratio 21.93
Price to Sales Ratio Twelve Trailing Months 2,214.82
Industry Price to Sales Ratio Twelve Trailing Months 101.19
Sector Price to Sales Ratio Twelve Trailing Months 28.34
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 295,338,000
Market Capitalization 126,995,340
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -46.18%
Reported EPS 12 Trailing Months -1.31
Reported EPS Past Year -0.67
Reported EPS Prior Year -0.78
Net Income Twelve Trailing Months -342,994,000
Net Income Past Year -342,994,000
Net Income Prior Year -234,632,000
Quarterly Revenue Growth YOY -15.40%
5-Year Revenue Growth -37.83%
Operating Margin Twelve Trailing Months -561,291.00%

Balance Sheet
Total Cash Most Recent Quarter 105,597,000
Total Cash Past Year 105,597,000
Total Cash Prior Year 145,647,000
Net Cash Position Most Recent Quarter 105,597,000
Net Cash Position Past Year 105,597,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 382,824,000
Total Stockholder Equity Prior Year 654,952,000
Total Stockholder Equity Most Recent Quarter 382,824,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -162,858,000
Free Cash Flow Per Share Twelve Trailing Months -0.55
Free Cash Flow Past Year -162,858,000
Free Cash Flow Prior Year -166,380,000

Options
Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.02
MACD Signal -0.03
20-Day Bollinger Lower Band 0.40
20-Day Bollinger Middle Band 0.58
20-Day Bollinger Upper Band 0.76
Beta -0.27
RSI 51.58
50-Day SMA 1.15
150-Day SMA 2.61
200-Day SMA 4.36

System
Modified 5/3/2025 4:26:16 AM EST